Compositions and methods of modulating macrophage activity

Patent metadata

Field	Value
Publication number	US-11554178-B2
Application number	US-201816625099-A
Country	US
Kind code	B2
Filing date	Jun 29, 2018
Priority date	Jun 30, 2017
Publication date	Jan 17, 2023
Grant date	Jan 17, 2023

Abstract

Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity. Provided is a method of treating a disease (e.g., a macrophage-associated disease, autoimmune disease, inflammatory disease, or a cancer of an organ in the intraperitoneal cavity), the method including intraperitoneally administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition or pharmaceutical composition. Provided is a silica nanoparticle non-covalently bound to a plurality of nucleic acids, wherein the silica nanoparticle has a net positive charge in the absence of the plurality of nucleic acids. Provided is a pharmaceutical composition including a nanoparticle composition as described herein, and a pharmaceutically acceptable excipient.

First claim

What is claimed is:

1. A method of delivering an anti-cancer agent or detectable agent to a tumor associated macrophage of a subject in need thereof, said method comprising intraperitoneally administering to said subject a therapeutically effective amount of an anionic non-functionalized nanoparticle composition wherein the nanoparticle comprises the anti-cancer agent or detectable agent, wherein the average longest dimension of the nanoparticle composition is from about 400 nm to about 800 nm, thereby delivering said anti-cancer agent or detectable agent to said tumor associated macrophage of said subject.

2. The method of claim 1 , wherein the nanoparticle composition increases the level or activity of T cells, B cells, or macrophages.

3. The method of claim 1 , wherein the average longest dimension of the nanoparticle composition is about 500 nm.

4. The method of claim 1 , wherein the nanoparticle comprises silica, iron, gold, poly(lactic-co-glycolic acid) (PLGA), phospholipid, or polystyrene.

5. The method of claim 1 , wherein the anti-cancer agent is imiquimod, resiquimod, or oseltamivir.

6. The method of claim 1 , wherein said anticancer agent is a nucleic acid, antibody, polymer, protein, steroid, or a small molecule.

7. The method of claim 1 , wherein said anti-cancer agent is a JAK2 inhibitor, a STAT3 inhibitor, an interferon, a CpG oligodeoxynucleotide (CpG ODN), a cytotoxic agent, tumor necrosis factor alpha (TNFα), tumor necrosis factor beta (TNFβ), a cyclic dinucleotide, or a Granulocyte-macrophage colony-stimulating factor (GM-CSF).

8. The method of claim 1 , wherein the detectable agent comprises a fluorescent dye, an enzyme used in an ELISA, a paramagnetic molecule, a radioisotope or radionuclide, or an iodinated contrast agent.

Assignees

• Hope City

Inventors

• Berlin Jacob
• Haber Tom
• Cornejo Yvonne

Classifications

• C12N2310/13

  Decoys · CPC title

• A61K38/21

  Interferons {[IFN]} · CPC title

• A61K49/0065

  the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K47/6923 Primary

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title